M3 muscarinic acetylcholine receptor–reactive Th17 cells in primary Sjögren’s syndrome-Reference-Cited by-同舟云学术

M3 muscarinic acetylcholine receptor–reactive Th17 cells in primary Sjögren’s syndrome

Published:2020-08-06 Issue:15 Volume:5 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Abe Saori^ORCID,Tsuboi Hiroto^ORCID,Kudo Hanae,Asashima Hiromitsu,Ono Yuko^ORCID,Honda Fumika,Takahashi Hiroyuki,Yagishita Mizuki,Hagiwara Shinya,Kondo Yuya^ORCID,Matsumoto Isao^ORCID,Sumida Takayuki

Funder

JSPS KAKENHI Grant

Japan Agency for Medical Research and Development

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/135982/files/pdf

Reference46 articles.

1. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies;Adamson;J Immunol,1983

2. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome

3. Th17 cells in primary Sjögren's syndrome: Pathogenicity and plasticity

4. Identification of IL-18 and Th17 Cells in Salivary Glands of Patients with Sjögren’s Syndrome, and Amplification of IL-17-Mediated Secretion of Inflammatory Cytokines from Salivary Gland Cells by IL-18

5. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in cellular and molecular pathways of salivary gland damage in Sjögren’s syndrome;Frontiers in Immunology;2024-07-10

2. Skin involvement in other autoimmune diseases;The Rose and Mackay Textbook of Autoimmune Diseases;2024

3. Screening biomarkers for Sjogren’s Syndrome by computer analysis and evaluating the expression correlations with the levels of immune cells;Frontiers in Immunology;2023-06-13

4. Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases;Frontiers in Immunology;2022-02-17

5. Targeted Therapy for Primary Sjögren’s Syndrome: Where are We Now?;BioDrugs;2021-11